Integral Health Asset Management Boosts Edgewise Therapeutics Stake

Institutional investor increases holdings in biotech firm by 50%

Mar. 14, 2026 at 8:48am

Got story updates? Submit your updates here. ›

Integral Health Asset Management LLC, an institutional investor, has increased its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 50%, now owning 1.5 million shares of the biopharmaceutical company. Edgewise Therapeutics is a clinical-stage firm focused on developing precision medicines for rare diseases, particularly in the areas of kidney disorders and neuromuscular diseases.

Why it matters

This investment signals Integral Health Asset Management's confidence in Edgewise Therapeutics' pipeline and future growth potential. As an institutional investor, Integral Health's increased stake could provide a vote of confidence for the biotech firm and its drug development efforts.

The details

According to a regulatory filing, Integral Health Asset Management LLC boosted its holdings in Edgewise Therapeutics by 500,000 shares in the third quarter of 2025, bringing its total stake to 1.5 million shares. This represents approximately 1.6% of Edgewise's total shares outstanding. The investment firm cited the company's promising pipeline, particularly its lead candidate EWTX-101, a novel inhibitor of the TRPC5 calcium channel that is being developed for the treatment of nephrotic syndromes and other kidney disorders.

  • Integral Health Asset Management LLC increased its stake in Edgewise Therapeutics by 500,000 shares in the third quarter of 2025.

The players

Integral Health Asset Management LLC

An institutional investor and asset management firm that has increased its stake in Edgewise Therapeutics by 50%, now owning 1.5 million shares of the biotech company.

Edgewise Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of rare diseases, particularly in the areas of kidney disorders and neuromuscular diseases.

Got photos? Submit your photos here. ›

The takeaway

Integral Health Asset Management's increased investment in Edgewise Therapeutics signals the institutional investor's confidence in the biotech firm's pipeline and growth potential. This vote of confidence could help bolster Edgewise's position as it continues to advance its drug development efforts in rare diseases.